Drug profile · INN
concizumab
ALHEMO
concizumab (ALHEMO) is a tissue factor pathway inhibitor inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — concizumab
- US status
- approved
- Class
- Blood and blood forming organs (B02)
- Route
- INJECTION
- Patents
- 0
- Programs
- 5
- Data quality
- 0.84
Quick answer
concizumab (ALHEMO) is a tissue factor pathway inhibitor inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Tissue factor pathway inhibitor inhibitor
Primary target: Tissue factor pathway inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is concizumab?
concizumab (ALHEMO) is a tissue factor pathway inhibitor inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for concizumab?
ALHEMO is a marketed brand name for concizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of concizumab?
concizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.